We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Vivus gets development & marketing rights to Tanabe's TA-1790
29 Mar 2018
Executive Summary
Vivus (sexual dysfunction products) has licensed worldwide development and marketing rights--excluding Japan, China, and specific Pacific Rim countries--to Tanabe Seiyaku's (cardiovascular diseases) Phase I phosphodiesterase type 5 (PDE5) inhibitor TA-1790 (avanafil). The drug candidate treats male and female sexual dysfunction through oral and local administration.
Deal Industry
Biotechnology
Pharmaceuticals
Deal Status
Final
Deal Type
Alliance
Co-Promotion
Includes Contract
R&D and Marketing (Licensing)
Reverse Licensing
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?